T. H. Bruemmendorf

发表

Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.

C. Bokemeyer, A. Zander, S. Schnittger, 2009, Cancer genetics and cytogenetics.

Drugging the unfolded protein response in acute leukemias

J. Panse, E. Chevet, Afshin Samali, 2015, Journal of Hematology & Oncology.

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial

H. Einsele, M. Pfreundschuh, A. Hinke, 2016, Haematologica.

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

M. Baccarani, H. Kantarjian, G. Martinelli, 2007 .

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

H. Kantarjian, J. Cortes, T. Fischer, 2007 .

Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

J. Cortes, M. Chandy, G. Ossenkoppele, 2008 .

Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.

C. Lengerke, T. Fischer, C. Waller, 2007 .

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib

E. Vellenga, H. Kantarjian, J. Cortes, 2012 .

Comprehensive Analysis of Telomere Biology in Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome: Further Evidence for a Common Mechanism

A. Traulsen, J. Panse, U. Germing, 2015 .

The Effects of Induction Chemotherapy and High-Dose Melphalan with Tandem Autologous Transplantation in Multiple Myeloma: The Prospective Randomized DSMM 2 Study.

N. Schmitz, H. Einsele, L. Kanz, 2007 .